Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Xofluza, Opdivo, Keytruda, Bavencio under PMDA Risk Review
May 13, 2019
- Pituitary Dysfunction Added to Significant Adverse Reaction for Opdivo: MHLW
May 10, 2019
- MHLW Launches Survey on Authorized Generics to Get Data for Chuikyo Debate
May 8, 2019
- Next Public-Private Confab Set for May 20 before Full-Swing Pricing Debate
May 8, 2019
- Entyvio’s Crohn’s Disease Indication in Line for Approval in May
May 7, 2019
- Chuikyo Agrees to Require Genetic Info Submission for Insurance Coverage of Cancer Genomic Panel Tests
April 25, 2019
- PMDA to Set Up New Consultation Services for RWD Use in Regulatory Submissions
April 24, 2019
- MOF Pitches Higher Copay for Pricey Drugs Deemed Not Cost Effective
April 23, 2019
- Lilly’s EGFR Antagonist, Japan’s 1st Avastin Biosimilar Now in Line for June Approval
April 22, 2019
- CEA Use in Reimbursement Decisions Our Ultimate Goal: MOF Budget Examiner
April 19, 2019
- Japan Drug Production Up 1.5% to 6.7 Trillion Yen in 2017: MHLW Survey
April 18, 2019
- LDP Junior Lawmakers to Launch Vaccine Study Group
April 17, 2019
- Entyvio’s Crohn’s Disease Use on Agenda for April 26 MHLW Panel Meeting
April 15, 2019
- CEFP Kicks Off Discussions towards 2020 Reimbursement Policy Reform
April 11, 2019
- Dupixent to Join Self-Injectable Drug List
April 11, 2019
- Supply of MSD’s Hep B Vaccine Heptavax Might Be Suspended as Early as October: MHLW
April 10, 2019
- MHLW Informally Notifies Drug Makers of Post-Oct. 1 NHI Prices
April 9, 2019
- Sakigake Status Granted to Takeda’s Narcolepsy Med, Ninlaro, Daiichi Sankyo’s Valemetostat and More
April 9, 2019
- Japan’s 1st Avastin Biosimilar Could Get Listing as Early as November; Lilly’s EGFR Up for MHLW Panel Review
April 8, 2019
- Epadel OTC to Be Reclassified as “Class 1” Category under Stricter Rules on Sales: MHLW Panel
April 5, 2019
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…